<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02885168</url>
  </required_header>
  <id_info>
    <org_study_id>2007-002319-16</org_study_id>
    <nct_id>NCT02885168</nct_id>
  </id_info>
  <brief_title>Modulation of Vasoreactivity in Septic Shock: Impact of Recombinant Protein C</brief_title>
  <acronym>PCA</acronym>
  <official_title>Modulation of Vasoreactivity in Septic Shock: Impact of Recombinant Protein C</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Central Hospital, Nancy, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Central Hospital, Nancy, France</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose is to demonstrate that vasoreactivity of patients with septic shock evaluated
      with dose-response curve is diminished in septic shock and ameliorated by activated protein C
      (APC).

      This amelioration is correlated to decrease of inflammation, decrease of reactive oxygen
      species (ROS) markers and increase of circulating catecholamines.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2008</start_date>
  <completion_date type="Actual">April 2009</completion_date>
  <primary_completion_date type="Actual">April 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Vascular reactivity measured with dose-response to phenylephrine</measure>
    <time_frame>baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Vascular reactivity measured with dose-response to phenylephrine</measure>
    <time_frame>4 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Vascular reactivity measured with dose-response to phenylephrine</measure>
    <time_frame>24 hours</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Septic Shock</condition>
  <arm_group>
    <arm_group_label>Shock + Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients treated with activated protein C</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Shock</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients not treated with activated protein C</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Recombinant Activated Protein C</intervention_name>
    <description>24 μg/kg/h during 96 hours - intravenous injection</description>
    <arm_group_label>Shock + Treatment</arm_group_label>
    <other_name>Xigris</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Near-infrared spectroscopy (NIRS)</intervention_name>
    <description>After baseline measurement, cuff is blown up to obtain a muscular saturation at 40% and then deflated. Reactive hyperthermia is measured. It is considered as an index for endothelial function.</description>
    <arm_group_label>Shock + Treatment</arm_group_label>
    <arm_group_label>Shock</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Phenylephrine</intervention_name>
    <description>Continuous administration of phenylephrine with electric syringe with increasing dosing levels: 0.0; 0.02; 0.05; 0.1; 0.2; 0.5; 0.75; 1.00; 1.50; 3.00; 4.50; 6.00; 9.00 et 12 µg/kg/min. Each level is maintained for 5 minutes. Administration of phenylephrine is stopped progressively with the same schema.
Arterial tension through an invasive approach is measured during the test.</description>
    <arm_group_label>Shock + Treatment</arm_group_label>
    <arm_group_label>Shock</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Blood sample</intervention_name>
    <description>Analysis of inflammation and cellular adhesion markers and free radicals</description>
    <arm_group_label>Shock + Treatment</arm_group_label>
    <arm_group_label>Shock</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - Patients with septic shock as determined by standard criteria (including infection and
        severe infection)

        Exclusion Criteria:

          -  Pregnant women

          -  Absence of signed informed consent. Due to gravity of medical situation of patients,
             inclusion will be possible after informed consent of a family member. As soon as
             possible, an informed consent will be obtained by patient

          -  Contraindication to Xigris: evolutive internal bleeding , intracranial pathology,
             neoplasia or brain involvement, concomitant heparin therapy &gt;= 15 IU/kg/h, known
             hemorrhagic diathesis except acute coagulopathy subsequent to sepsis, severe chronic
             liver disease, platelet count &lt; 30000 x 10^6/L, high bleeding risk, known
             hypersensibility to drotrecogin alfa (activated), one of excipients or bovine thrombin
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bruno LEVY</last_name>
    <role>Principal Investigator</role>
    <affiliation>Réanimation Médicale - Hôpital de Brabois - CHRU Nancy</affiliation>
  </overall_official>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 26, 2016</study_first_submitted>
  <study_first_submitted_qc>August 26, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2016</study_first_posted>
  <last_update_submitted>August 26, 2016</last_update_submitted>
  <last_update_submitted_qc>August 26, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 31, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>vasoreactivity</keyword>
  <keyword>recombinant activated protein C</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Shock</mesh_term>
    <mesh_term>Shock, Septic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Phenylephrine</mesh_term>
    <mesh_term>Oxymetazoline</mesh_term>
    <mesh_term>Protein C</mesh_term>
    <mesh_term>Drotrecogin alfa activated</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

